Cargando…

Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors

BACKGROUND: Hidradenitis suppurativa (HS) is an independent risk factor for the development of subclinical atherosclerosis. Tumour necrosis factor (TNF) inhibitors are effective for the treatment of recalcitrant moderate‐to‐severe HS. However, the effect of treatment with TNF inhibitors on subclinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Oba, Muazzez Cigdem, Askin, Ozge, Gunver, Mehmet Guven, Kocaarslan, Gokce, Alis, Deniz Can, Engin, Burhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155849/
https://www.ncbi.nlm.nih.gov/pubmed/36973990
http://dx.doi.org/10.1111/srt.13302
_version_ 1785036414791974912
author Oba, Muazzez Cigdem
Askin, Ozge
Gunver, Mehmet Guven
Kocaarslan, Gokce
Alis, Deniz Can
Engin, Burhan
author_facet Oba, Muazzez Cigdem
Askin, Ozge
Gunver, Mehmet Guven
Kocaarslan, Gokce
Alis, Deniz Can
Engin, Burhan
author_sort Oba, Muazzez Cigdem
collection PubMed
description BACKGROUND: Hidradenitis suppurativa (HS) is an independent risk factor for the development of subclinical atherosclerosis. Tumour necrosis factor (TNF) inhibitors are effective for the treatment of recalcitrant moderate‐to‐severe HS. However, the effect of treatment with TNF inhibitors on subclinical atherosclerosis in HS patients has not been previously investigated. OBJECTIVES: In this study, we aimed to assess changes in biochemical parameters (fasting blood glucose and lipid levels) and carotid intima‐media thickness (CIMT) values in Hurley stage II and III HS patients undergoing treatment with TNF inhibitors. METHODS: This was a single center prospective study including 30 patients with Hurley stage II and III HS and 30 healthy controls (HCs). Baseline values of biochemical parameters and CIMT were compared to the values recorded after at least 6 months of TNF inhibitor therapy. RESULTS: CIMT values of the HS patients significantly exceeded those of HCs (for right p = 0.011 and for left p = 0.017). After at least 6 months of TNF inhibitor therapy, there was a statistically significant decrease in fasting blood glucose (p = 0.001), whereas total cholesterol levels significantly increased (p = 0.001). CIMT values also significantly increased (for right p = 0.02 and for left p = 0.01). STUDY LIMITATIONS AND CONCLUSIONS: Small sample size is limitation of the current study. Our study shows that patients with Hurley stage II and III HS undergoing TNF inhibitor therapy are under risk for progression of subclinical atherosclerosis.
format Online
Article
Text
id pubmed-10155849
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-101558492023-08-11 Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors Oba, Muazzez Cigdem Askin, Ozge Gunver, Mehmet Guven Kocaarslan, Gokce Alis, Deniz Can Engin, Burhan Skin Res Technol Original Articles BACKGROUND: Hidradenitis suppurativa (HS) is an independent risk factor for the development of subclinical atherosclerosis. Tumour necrosis factor (TNF) inhibitors are effective for the treatment of recalcitrant moderate‐to‐severe HS. However, the effect of treatment with TNF inhibitors on subclinical atherosclerosis in HS patients has not been previously investigated. OBJECTIVES: In this study, we aimed to assess changes in biochemical parameters (fasting blood glucose and lipid levels) and carotid intima‐media thickness (CIMT) values in Hurley stage II and III HS patients undergoing treatment with TNF inhibitors. METHODS: This was a single center prospective study including 30 patients with Hurley stage II and III HS and 30 healthy controls (HCs). Baseline values of biochemical parameters and CIMT were compared to the values recorded after at least 6 months of TNF inhibitor therapy. RESULTS: CIMT values of the HS patients significantly exceeded those of HCs (for right p = 0.011 and for left p = 0.017). After at least 6 months of TNF inhibitor therapy, there was a statistically significant decrease in fasting blood glucose (p = 0.001), whereas total cholesterol levels significantly increased (p = 0.001). CIMT values also significantly increased (for right p = 0.02 and for left p = 0.01). STUDY LIMITATIONS AND CONCLUSIONS: Small sample size is limitation of the current study. Our study shows that patients with Hurley stage II and III HS undergoing TNF inhibitor therapy are under risk for progression of subclinical atherosclerosis. John Wiley and Sons Inc. 2023-03-05 /pmc/articles/PMC10155849/ /pubmed/36973990 http://dx.doi.org/10.1111/srt.13302 Text en © 2023 The Authors. Skin Research and Technology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Oba, Muazzez Cigdem
Askin, Ozge
Gunver, Mehmet Guven
Kocaarslan, Gokce
Alis, Deniz Can
Engin, Burhan
Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors
title Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors
title_full Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors
title_fullStr Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors
title_full_unstemmed Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors
title_short Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors
title_sort subclinical atherosclerosis in patients with hidradenitis suppurativa treated with tnf inhibitors
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155849/
https://www.ncbi.nlm.nih.gov/pubmed/36973990
http://dx.doi.org/10.1111/srt.13302
work_keys_str_mv AT obamuazzezcigdem subclinicalatherosclerosisinpatientswithhidradenitissuppurativatreatedwithtnfinhibitors
AT askinozge subclinicalatherosclerosisinpatientswithhidradenitissuppurativatreatedwithtnfinhibitors
AT gunvermehmetguven subclinicalatherosclerosisinpatientswithhidradenitissuppurativatreatedwithtnfinhibitors
AT kocaarslangokce subclinicalatherosclerosisinpatientswithhidradenitissuppurativatreatedwithtnfinhibitors
AT alisdenizcan subclinicalatherosclerosisinpatientswithhidradenitissuppurativatreatedwithtnfinhibitors
AT enginburhan subclinicalatherosclerosisinpatientswithhidradenitissuppurativatreatedwithtnfinhibitors